ATP-responsive DNA-graphene hybrid nanoaggregates for anticancer drug delivery

Ran Mo; Tianyue Jiang; Wujin Sun; Zhen Gu

doi:10.1016/j.biomaterials.2015.01.053

ATP-responsive DNA-graphene hybrid nanoaggregates for anticancer drug delivery

Biomaterials. 2015 May:50:67-74. doi: 10.1016/j.biomaterials.2015.01.053. Epub 2015 Feb 14.

Authors

Ran Mo¹, Tianyue Jiang², Wujin Sun², Zhen Gu³

Affiliations

¹ Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC 27695, USA; Center for Nanotechnology in Drug Delivery and Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, China.
² Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC 27695, USA; Center for Nanotechnology in Drug Delivery and Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
³ Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC 27695, USA; Center for Nanotechnology in Drug Delivery and Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: zgu@email.unc.edu.

Abstract

Stimuli-triggered drug delivery systems are primarily focused on the applications of the tumor microenvironmental or cellular physiological cues to enhance the release of drugs at the target site. In this study, we applied adenosine-5'-triphosphate (ATP), the primary "energy molecule", as a trigger for enhanced release of preloaded drugs responding to the intracellular ATP concentration that is significantly higher than the extracellular level. A new ATP-responsive anticancer drug delivery strategy utilizing DNA-graphene crosslinked hybrid nanoaggregates as carriers was developed for controlled release of doxorubicin (DOX), which consists of graphene oxide (GO), two single-stranded DNA (ssDNA, denoted as DNA1 and DNA2) and ATP aptamer. The single-stranded DNA1 and DNA2 together with the ATP aptamer serve as the linkers upon hybridization for controlled assembly of the DNA-GO nanoaggregates, which effectively inhibited the release of DOX from the GO nanosheets. In the presence of ATP, the responsive formation of the ATP/ATP aptamer complex causes the dissociation of the aggregates, which promoted the release of DOX in the environment with a high ATP concentration such as cytosol compared with that in the ATP-deficient extracellular fluid. This supports the development of a novel ATP-responsive platform for targeted on-demand delivery of anticancer drugs inside specific cells.

Keywords: ATP responsive; DNA; Drug delivery; Graphene oxide; Nanomedicine.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adenosine Triphosphate / pharmacology*
Antineoplastic Agents / pharmacology*
Cell Death / drug effects
DNA, Single-Stranded / chemistry*
Doxorubicin / pharmacology
Drug Delivery Systems*
Endocytosis / drug effects
Graphite / chemistry*
HeLa Cells
Humans
Intracellular Space / metabolism
Nanoparticles / chemistry*
Particle Size
Spectrometry, Fluorescence

Substances

Antineoplastic Agents
DNA, Single-Stranded
Graphite
Doxorubicin
Adenosine Triphosphate

Abstract

Publication types

MeSH terms

Substances

Grants and funding